INTRODUCTION {#s1}
============

Among women in the world, breast cancer is the most common cancer with an estimated 1.67 million new cases diagnosed (25% of all cancers) and it was the most frequent cause of cancer death (522,000 deaths, 14.7% of total) in 2012 \[[@R1]\]. Although comprehensive treatment is available,, including radical surgery and adjuvant therapy, the prognosis of breast cancer patients is still far from optimistic \[[@R2]\]. Several common clinicopathological parameters, which include tumor size, lymph node status, histological grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor-2 (HER-2) have been extensively applied in the clinic \[[@R3]\]. However, they do not accurately predict an individual\'s prognosis \[[@R4]\]. It is imperative to explore new prognostic factors to guide treatment and ameliorate survival rates for breast cancer patients \[[@R4]\].

E-cadherin is an essential intercellular adhesion molecule that combines with catenins to form an E-cadherin/β-catenin/α-catenin complex, which is further linked to the actin cytoskeleton \[[@R5]\]. It plays an important role not only in mediating stability of cell adhesion and cell polarity but also in maintaining the integrity of structure and function in epithelial tissues \[[@R6], [@R7]\]. Downregulated expression of E-cadherin destroys the intracellular junction and thus epithelial cells acquire the ability to migrate. Consequently, decreased expression of E-cadherin facilitates tumor invasion and metastasis \[[@R8], [@R9]\]. Reduced expression of E-cadherin caused by oncocytes involves several molecular mechanisms: *CDH1* gene mutation, *CDH1* promoter hypermethylation, suppression of RNA transcription, and matriptase activation \[[@R10]\].

It has been reported by Rakha *et al*. that downregulated expression of E-cadherin was correlated with poor survival in a study of 1,516 breast cancer patients \[[@R11]\]. However, Gillett *et al*. assessed the aberrant expression of E-cadherin in 470 cases of infiltrating ductal cancer (IDC) and concluded that low-expression of E-cadherin was a favorable prognostic factor \[[@R12]\]. Wang *et al*. found there was no relationship between E-cadherin expression and prognostic \[[@R13]\]. Therefore, we conducted a meta-analysis to evaluate the association between E-cadherin low-expression and overall survival (OS), disease-free survival (DFS), and clinicopathological parameters in breast cancer.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

A total of 2,192 citations were potentially identified for inclusion using the described search strategies. Through reviewing the title and abstracts, 1,952 papers were excluded. Subsequently, an additional 164 records were excluded for the following reasons: They were reviews, conference abstracts, and experimental studies; the source of the tissue was not breast cancer; and, the target protein was not E-cadherin. We then systematically read the full text of the remaining 76 articles and filtered out an additional 43 papers. Among the excluded papers, 21 studies were not associated with survival, 19 studies had no sufficient survival data to analyze and three studies had overlapped data with other published trials. Ultimately, 33 studies \[[@R11]--[@R43]\] were included (Figure [1](#F1){ref-type="fig"}).

![Flow diagram of the study selection process](oncotarget-08-16445-g001){#F1}

Study characteristics {#s2_2}
---------------------

The fundamental features of the identified articles are shown in Table [1](#T1){ref-type="table"}. The total number of patients was 7,353, ranging from 29 to 1,516 in any one study with mean ages of 46--60 years. These studies were published between 1994 and 2016. For the prognostic indicator of reduced E-cadherin expression in breast cancer, 15 articles reported both OS and DFS, 10 articles reported OS, and eight articles reported DFS.

###### Characteristics of studies included in our meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Author       year   country      Mean age\   stage   N      location   Median Follow-up\   Cut-off\      Method   Survival   HR estimated   NOS
                                   (year)                                (month)             value                                            
  ------------ ------ ------------ ----------- ------- ------ ---------- ------------------- ------------- -------- ---------- -------------- -----
  Asgeirsson   2000   Iceland      58          NR      108    M,         71                  50%           IHC      DFS        HR             9

  Yu           2015   China        NR          I-III   169    M, C       63.5                165           IHC      DFS, OS    Curves         7

  Pedersen     2002   Norway       55          I-IV    61     M          79                  5%            IHC      OS         Curves         7

  Siitonen     1995   Finland      60          I-IV    109    NR         51                  10%           IHC      DFS        A              7

  Charpin      1998   France       55          I-III   179    M          67                  4%            IHC      OS         Curves         8

  Kashiwagi    2010   Japan        58          I-III   574    M          45.7                30%           IHC      DFS, OS    Curves         7

  Wang         2015   China        47          I-III   571    M          54                  Scores ≤ 99   IHC      DFS, OS    A              8

  Shi          2015   China        51          NR      96     M, C       65.2                28%           IHC      OS         HR             9

  Pang         2013   China        46          I-III   170    M          75                  Scores ≤ 3    IHC      DFS, OS    HR             8

  Wang         2014   China        54          I-III   29     NR         50                  25%           IHC      DFS, OS    A              8

  Liu          2014   china        51          NR      100    C          65.4                28%           IHC      OS         HR             8

  Yang         2015   China        NR          NR      125    M          89                  Scores \< 6   IHC      DFS, OS    HR             7

  Bankfalvi    1999   Germany      NR          I-IV    55     M          7                   75%           IHC      DFS, OS    Curves         7

  Heimann      2000   America      57          NR      168    NR         168                 25%           IHC      DFS        HR             9

  Pistelli     2014   Italy        54          I-III   81     M          52.4                30%           IHC      DFS, OS    HR             8

  Gillett      2001   UK           53          III     470    M, C       NR                  Scores ≤ 1    IHC      DFS, OS    A              6

  Kim          2010   Korea        49          I-IV    98     M, C       67.8                70%           IHC      OS         HR             7

  Lipponen     1994   Finland      57          I-IV    207    M          171.6               50%           IHC      OS         Curves         6

  Zhou         2016   China        NR          I-IV    119    M, C       60                  10%           IHC      DFS, OS    Curves         7

  Li           2014   China        NR          I-III   250    NR         60                  Scores \< 3   IHC      DFS        HR             7

  Park         2007   Norway       54          I-III   196    M          40                  Scores ≤ 3    IHC      DFS        Curves         7

  Ricciardi    2015   Italy        59          I-IV    45     M          NR                  30%           IHC      OS         HR             7

  Zhang        2015   China        50          I-III   408    NR         16                  NR            IHC      DFS, OS    A              7

  Rakha        2005   UK           53          I-III   1516   M          56                  Scores ≤ 1    IHC      DFS, OS    HR             8

  Saadatmand   2012   Netherland   57          I-IV    502    M          228                 53%           IHC      DFS        HR             8

  Szasz        2011   Hungary      60          I-III   197    M          111                 NR            IHC      DFS        Curves         6

  Brzozowska   2012   Poland       58          I-III   89     NR         113.4               70%           IHC      DFS, OS    Curves         7

  Yoshida      2001   Japan        54          I-IV    171    NR         59.2                Scores \< 1   IHC      DFS, OS    Curves         7

  Eljuga       2012   Croatia      NR          I-III   134    M          NR                  Scores ≤ 2    IHC      OS         Curves         7

  Kavgaci      2010   Turkey       51          I-III   76     M          93.6                10%           IHC      DFS, OS    Curves         8

  Lim          2002   Korea        49          I-III   128    M          58.5                70%           IHC      OS         A              8

  Kawahara     1997   Japan        52          I-IV    98     NR         27                  Scores ≤ 4    IHC      DFS        Curves         7

  Liu          2006   China        49          I-III   54     M          36.5                10%           IHC      OS         A              6

                                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------

NR, not reported; M, membrane; C, cytoplasm; IHC, immunohistochemistry; DFS, disease-free survival; OS, overall survival; HR: hazard ratio; Curves, extrapolated from Kaplan--Meier curves; A, calculated based on the available information; NOS, Newcastle--Ottawa Scale.

Impact of reduced E-cadherin expression on OS and DFS {#s2_3}
-----------------------------------------------------

The overall analysis revealed that E-cadherin-negative breast cancer patients had a higher risk of mortality (pooled HR 1.79, 95% CI 1.41--2.27, Figure [2](#F2){ref-type="fig"}) with heterogeneity (I^2^ = 67.3%, *P* \< 0.001). To investigate the source of the OS heterogeneity, subgroup analysis and meta-regression were performed according to publication year, study location, HR estimate, IHC scoring criteria, subcellular localization and pathological types (Table [2](#T2){ref-type="table"}). In subgroup analysis, the pooled HRs directly extracted from studies and obtained from Kaplan--Meier curves were 1.77 (95% CI 1.41--2.28) and 1.92 (95% CI 1.55--2.39), demonstrating that reduced expression of E-cadherin was significantly associated with poor OS. Meta-regression analysis indicated that there was no statistically significant difference among subgroups (*P* = 0.637). When the scoring criteria of IHC was taken into consideration, the pooled HR of E-cadherin expression in percentage group was 2.19 (95% CI 1.78--2.70), indicating that there was a significant relationship between reduced expression of E-cadherin and poor OS. In meta-regression analysis, results showed that the difference among subgroups was statistically significant (*P* = 0.024). Pooled HRs were 1.57 (95% CI 1.17--2.10) in the membrane E-cadherin expression group and 2.80 (95% CI 1.92--4.10) in the membrane and cytoplasm E-cadherin co-expression group. Meta-regression analysis showed that there was no statistically significant difference between subgroups (*P* = 0.061).

![Forest plot of hazard ratio (HR) for the correlation between reduced E-cadherin expression and OS in breast cancer patient](oncotarget-08-16445-g002){#F2}

###### Stratified analysis of pooled hazard ratios of breast cancer patients with reduced E-cadherin expression on OS and DFS

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stratified\         OS                 DFS                                                                                                               
  analysis                                                                                                                                                 
  ------------------- ------------------ ------------------ ------- ---------- ------------------ ------------------ ------------------ ---------- ------- ----------
  Year                                   0.937                                 0.791                                                                       

  \< 2010             1.32 (1.12,1.56)   1.85 (1.22,2.81)           79.0%      \< 0.001           1.38 (1.20,1.59)   1.69 (1.19,2.40)              79.9%   \< 0.001

  ≥ 2010              1.46 (1.23,1.73)   1.77 (1.30,2.41)   57.4%   0.002      1.49 (1.29,1.73)   1.58 (1.21,1.99)   63.2%              0.001              

  Nation                                 0.209                                 0.925                                                                       

  Asia                1.56 (1.30,1.88)   2.12 (1.45,3.09)           68.9%      \< 0.001           1.44 (1.21,1.71)   1.61 (1.13,2.28)              69.6%   \< 0.001

  Non-Asia            1.27 (1.08,1.48)   1.51 (1.09,2.08)   65.8%   0.001      1.43 (1.27,1.61)   1.63 (1.24,2.14)   74.3%              \< 0.001           

  HR estimate                            0.637                                 0.485                                                                       

  Directly            1.65 (1.30,2.09)   1.77 (1.41,2.28)           55.5%      0.028              1.67 (1.23,2.26)   1.63 (1.40,1.91)              62.4%   0.009

  Calculated          0.99 (0.83,1.19)   1.60 (0.93,2.75)   81.3%   \< 0.001   1.13 (0.75,1.71)   0.94 (0.79,1.13)   74.1%              0.004              

  Curves              1.92 (1.55,2.39)   1.92 (1.55,2.39)   0.0%    0.693      1.93 (1.59,2.34)   1.93 (1.59,2.34)   0.0%               0.512              

  Scoring criteria                       0.024                                 0.423                                                                       

  Percentage          2.19 (1.78,2.70)   2.19 (1.78,2.70)           0.0%       0.613              2.11 (1.52,2.92)   2.13 (1.68,2.70)              38.5%   0.135

  Intensity           0.93 (0.74,1.16)   1.21 (0.68,2.15)   72.9%   0.011      1.19 (0.76,1.87)   1.09 (0.92,1.30)   79.6%              0.001              

  Combined            1.22 (1.00,1.48)   1.33 (0.84,2.10)   74.8%   0.003      1.58 (1.20,2.09)   1.47 (1.27,1.70)   63.3%              0.004              

  Location                               0.061                                 0.031                                                                       

  M                   1.24 (1.09,1.41)   1.57 (1.17,2.10)           71.8 %     \< 0.001           1.29 (1.16,1.45)   1.37 (1.07,1.75)              73.8%   \< 0.001

  C, M                2.80 (1.92,4.10)   2.80 (1.92,4.10)   0%      0.925      3.35 (2.03,5.53)   3.35 (2.03,5.53)   0.0%               0.529              

  Pathological type                                                                                                                                        

  IDC                 1.13 (0,97,1.32)   1.61 (1.09,2.39)           78.1%      \< 0.001           1.12 (0.95,1.31)   1.58 (1.03,2.44)              82.4%   \< 0.001
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

23 studies evaluated the relationship between decreased E-cadherin expression and DFS, the results showed that E-cadherin low-expression predicted poorer disease-free survival (pooled HR 1.62, 95% CI 1.31--1.99, Figure [3](#F3){ref-type="fig"}) with significant heterogeneity (I^2^ = 70.9%, *P* \< 0.001) of patients with breast cancer. We also conducted subgroup analysis and meta-regression to explain the heterogeneity from six aspects, which are detailed in Table [2](#T2){ref-type="table"}. In subgroup analysis, the pooled HRs directly extracted from studies and obtained from Kaplan--Meier curves were 1.63 (95% CI 1.40--1.91) and 1.93 (95% CI 1.59--2.34). Both of them showed that reduced expression of E-cadherin was significantly associated with disease progression. No significant heterogeneity was found in meta-regression analysis (*P* = 0.485). Pooled HRs were 2.11 (95% CI 1.52--2.92) in the percentage group and 1.47 (95% CI 1.27--1.70) in the complex score group. Meta-regression analysis showed that no significant statistical difference was found (*P* = 0.423). The results showed that in the group of membrane location (pooled HR 1.37, 95% CI 1.07--1.75) and group of membrane and cytoplasm location (pooled HR 3.35, 95% CI 2.03--5.53), indicating that downregulated expression of E-cadherin was correlated with poor DFS. Importantly, a significant heterogeneity was observed in meta-regression analysis (*P* = 0.031).

![A. Forest plot of hazard ratio (HR) for the association between reduced E-cadherin expression and DFS in breast cancer patient](oncotarget-08-16445-g003){#F3}

Evaluation of reduced E-cadherin expression and clinicopathological characteristics {#s2_4}
-----------------------------------------------------------------------------------

As illustrated in Table [3](#T3){ref-type="table"}, E-cadherin low-expression was significantly associated with lymph node (positive vs. negative: OR 1.55, 95% CI 1.15--2.10), tumor size (≥ 2 cm vs. \< 2 cm, OR 1.38, 95% CI 1.18--1.60), histological grade (II--III vs. I: OR 1.44, 95% CI 1.06--1.96), TNM stage (T3/T4 vs. T1/T2: OR 2.44, 95% CI 1.75--3.41), and PR status (negative vs. positive: OR 1.44, 95% CI 1.10--1.88). However, no significant correlation was found between E-cadherin low-expression and ER status (negative vs. positive: OR 1.32, 95% CI 0.94--1.84), HER-2 status (≥ 2+ vs. 1+ OR 1.36, 95% CI 0.86--2.16), onset age (≥ 50 vs. \< 50 OR 1.03, 95% CI 0.85--1.24), menstrual status (post vs. premenstrual OR 1.20, 95% CI 0.90--1.60), and pathological type (IDC vs. others OR 0.77, 95% CI 0.59--1.00).

###### Meta-analysis of reduced E-cadherin expression and clinicopathological features in breast cancer

                                     No. of studies   Pheterogeneity   I^2^(%)   Effect Model   Pooled OR(95%CI)   *P* Value
  ---------------------------------- ---------------- ---------------- --------- -------------- ------------------ -----------
  Tumor size(≥ 2 vs.\< 2)            12               0.734            0.0       Fixed model    1.38 (1.18,1.60)   \< 0.001
  Age(≥ 50 vs.\< 50)                 12               0.205            25.0      Fixed model    1.03 (0.85,1.24)   0.706
  Histological grade(II/IIIvs.I)     14               0.001            63.6      Random model   1.44 (1.06,1.96)   0.02
  TNM stage(T3/T4vs.T1/T2)           7                0.086            45.9      Fixed model    2.44 (1.75,3.41)   \< 0.001
  Pathological type(IDC vs.Others)   7                0.629            0.0       Fixed model    0.77 (0.59,1.00)   0.054
  Menopause status(Post vs.Pre)      6                0.341            11.6      Fixed model    1.20 (0.90,1.60)   0.219
  Lymph node status(+ vs.−)          15               \< 0.001         72.1      Random model   1.55 (1.15,2.10)   0.005
  ER status(− vs.+)                  12               0.002            61.8      Random model   1.32 (0.94,1.84)   0.108
  PR status(− vs.+)                  8                0.399            4.0       Fixed model    1.44 (1.10,1.88)   0.007
  Her2 status(≥ 2+ vs.1+)            5                0.197            33.6      Fixed model    1.36 (0.86,2.16)   0.185

Sensitivity analysis {#s2_5}
--------------------

We further performed sensitivity analysis to gauge the stability of our results with respect to OS, DFS, and clinicopathological characteristics. The plots illustrated the robustness of our results because excluding any single study did not significantly influence pooled HRs or ORs (Figure [4](#F4){ref-type="fig"}).

![Sensitivity analysis in this meta-analysis\
(**A**) Sensitivity analysis for the reduced E-cadherin expression with OS. (**B**) Sensitivity analysis for the reduced E-cadherin expression with DFS.](oncotarget-08-16445-g004){#F4}

Publication bias {#s2_6}
----------------

To assess the publication bias in this meta-analysis, we used both Egger\'s test and Begg\'s funnel plots. Both of these tests present the potential proof of the asymmetry of investigating the reduced expression of E-cadherin on OS (P~Egger~= 0.001, P~Begg~= 0.388). Trim-and-fill analysis showed that after incorporating six additional articles, the funnel plots were symmetrical and E-cadherin low-expression was positively correlated with poor OS (corrected HR 1.50, 95% CI 1.20--1.87). Meanwhile, the impact of absent E-cadherin expression on clinicopathological characteristics, Egger\'s test indicated publication bias existed in lymph node metastasis (P~Egger~= 0.048). Trim-and-fill analysis was conducted and the results showed that abnormal expression of E-cadherin was significantly correlated with lymph node metastasis after incorporating two additional articles (corrected OR 1.39, 95% CI 1.04--1.87). Referring to other indicators, no publication bias was found in these articles. Funnel plots are shown in Figure [5](#F5){ref-type="fig"}.

![Funnel plot for the assessment of publication bias in this study\
(**A**) Funnel plot of trim-and-fill analysis for the reduced E-cadherin expression with OS (**B**) Funnel plot for the reduced E-cadherin expression with DFS.](oncotarget-08-16445-g005){#F5}

DISCUSSION {#s3}
==========

E-cadherin, a member of cadherin superfamily of transmembrane glycoproteins, is a linker protein of cell-cell junctions \[[@R44]\]. It is well-known that the functional loss of E-cadherin has been viewed as the most important hallmark of epithelial--mesenchymal transition (EMT), which induces tumor cell dissemination and subsequently increases cell migration and invasion \[[@R45], [@R46]\]. Besides, the absent of E-cadherin expression has an inseparable relationship with resistance of tumor cells to chemotherapy and radiotherapy \[[@R47]\] and causes cancer cells to present apparent properties of cancer stem cells (CSCs) \[[@R48]\]. Many studies have evaluated the association between decreased E-cadherin expression and the prognosis of breast cancer patients. However, the results are inconsistent. We summarized outcomes from a total of 33 individual studies that included 7,353 breast cancer patients. From this analysis we reached the conclusion that reduced E-cadherin expression significantly predicted poor OS and DFS. Furthermore, the downregulated expression of E-cadherin was correlated with tumor size, lymph node status, TNM stage, and histological grade.

E-cadherin is often split into fragments in the cytoplasm, which in theory its functions would not play an inhibitory effect on EMT \[[@R46], [@R49]\]. As a result, we further performed a subgroup according to the location of E-cadherin expression. The results showed that E-cadherin expression on membrane was significantly associated with OS (HR 1.57, 95% CI 1.17--2.10) and DFS (HR 1.37, 95% CI 1.07--1.75), which demonstrated that the prognostic role of E-cadherin expressed on the membrane is more precise and meaningful. Considering the heterogeneity of intra-tumor, we conduct a subgroup analysis according to the pathological types of breast cancer. In the subgroup of IDC, the pooled HRs showed that reduced expression of E-cadherin was significantly associated with poor OS (HR 1.62, 95% CI 1.08-2.43) and DFS (HR 1.60, 95% CI 1.09--2.34). It\'s necessary to analyze the heterogeneity of inter-tumor cells as the prognostic values of E-cadherin may quite different in breast cancer stem cell (CSC) subpopulations \[[@R48]\]. However, it\'s a pity that there is no articles explored the correlation between E-cadherin expression in CSCs and prognosis, and more original research need to be conducted at this field in the future.

When pooling survival data on OS and DFS, we observed significant heterogeneity among articles. Consequently, meta-regression analysis was conducted and it suggested that IHC scoring criteria and subcellular localization might be vital variables associated with this heterogeneity. In subgroup analysis of IHC scoring criteria, the heterogeneity of E-cadherin expression calculated by percentage group was less than 50%, while the other groups had significant heterogeneity. The potential reason could be that compared with the detection method of staining intensity, assessing the percentage of positive cells was more objective and had more practical clinical implications. In subgroup analysis according to locations of E-cadherin expression, heterogeneity was significant in membrane E-cadherin expression group. It may mainly come from the differences in sample sizes, molecular subtypes, demographic or clinicopathologic data of observational studies. Compared with analyses performed in 2006 \[[@R50]\], the advantages of this meta-analysis were not only that it included more studies and subjects to confirm clinical validity but also that it provided more rigorous evidence to support the results. More importantly, we demonstrated that the prognostic role of E-cadherin expressed on the membrane is more meaningful. Furthermore, we assessed the association between E-cadherin expression and clinicopathological characteristics for breast carcinoma patients.

There were limitations in our meta-analysis. First, different primary antibody sources and antibody dilution ratios can lead to differences in IHC sensitivity. Second, there was no uniform scoring criteria to define E-cadherin positive expression. Furthermore, cut-off values defining reduced E-cadherin expression varied from 5 to 70% without an optimal threshold. Third, HRs estimated from available data and obtained from Kaplan--Meier curves were less reliable owing to inaccuracies in the calculation of censored data. Fourth, we had to exclude studies that had no statistical significance because it was difficult to obtain specific data with which to calculate HRs. Finally, meaningful results trended to be published in English, whereas negative ones were more likely to be published in native languages.

In conclusion, our meta-analysis suggest that reduced E-cadherin expression was not only significantly associated with poorer OS and DFS but also correlated with clinicopathological characteristics including tumor size, lymph node status, TNM stage, and histological grade of breast cancer patients. E-cadherin low-expression might be a useful biomarker for predicting poorer prognosis, especially in the location of membrane, and could be a valuable therapeutic target for breast cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched for studies on E-cadherin expression and its association with breast cancer prognosis in electronic databases: PubMed, EMBASE, and Cochrane library updated to May 15, 2016. Articles were qualified using the following combined keywords: "breast", "mammary", "tumor", "cancer", "neoplasm", "E-cadherin", "E-CAD", "cadherin-1", "prognostic", and "survival". References from eligible literature were scanned to minimize any deviation caused during the research process.

Inclusion criteria {#s4_2}
------------------

Articles were required to meet the following inclusion criteria: (1) patients diagnosed with breast cancer using pathological and histological examinations; (2) E-cadherin expression was detected in primary tumor tissues; (3) full text, original research articles published in English; (4) statistical results that included hazard ratios (HRs) and 95% confidence intervals (CIs) reported directly or calculated from demographic data or survival curves; and (5) independent E-cadherin expression level data. Only studies with more details and larger sample sizes were selected if duplicate data from other articles occurred. Reviews, letters, conference abstracts, and comments were excluded.

Quality assessment {#s4_3}
------------------

The Newcastle-Ottawa quality assessment scale (NOS) was applied to estimate the quality of nonrandomized studies, specifically cohort studies by two investigators independently. According to the NOS, three perspectives were assessed: selection, comparability, and outcomes. Scores higher than six were considered high quality.

Data extraction {#s4_4}
---------------

Two researchers extracted the following data independently from qualified studies: (1) publication data including authors, year and country; (2) experimental data including tissue origin, location of E-cadherin expression, percentage of E-cadherin positive cells and cut-off values; (3) demographic data including number of subjects analyzed, ages, and follow-ups; (4) clinicopathological data including tumor size, lymph node status, ER, PR, HER-2, menopausal state, pathologic type, histologic type, and TNM stage; and (5) statistical data including survival analysis, HRs and 95% CIs. Inconsistencies were resolved through negotiation and consultation.

Statistical analysis {#s4_5}
--------------------

In this meta-analysis, HRs with 95% CIs was applied as appropriate values to measure the impact of reduced E-cadherin expression on survival in breast cancer. In some studies, the value of HR and the 95% CI describing OS and/or DFS could be obtained directly. Otherwise, many studies displaying survival rates with *P* values from log-rank tests or Kaplan--Meier survival curves could also be extrapolated using the method of Parmar and Tierney \[[@R51]\]. For the pooled analysis of the correlation between decreased E-cadherin expression and clinicopathological features, odds ratios (ORs) and their 95% CIs were evaluated. Heterogeneity of the studies was evaluated by the Chi-square-based *Q* test and I^2^. I^2^ \< 50% and *P* \> 0.05 were considered as acceptable heterogeneity, in which case the fixed-effect model test was performed. Otherwise, the random-effect model test was chosen if significant heterogeneity existed (I^2^ \> 50% or *P* \< 0.05). Subgroup analysis and meta-regression analysis were performed to detect the source of the heterogeneity. Publication bias was assessed using Begg\'s test and Egger\'s test. Sensitivity analysis was carried out to evaluate the stability of the pooled results using sequential omission of individual studies. Furthermore, if multivariate and univariate analyses were both obtainable, the former was chosen. All *P* values were two-sided and *P* \< 0.05 was considered statistically significant. All statistical analyses were performed with Stata Version 12.0 (Stata Corporation, College Station, TX, USA).
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